Single-Cell Map of Immune and Lymphoma Cells in B-cell Non-Hodgkin's Lymphoma

NAActive, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 9, 2021

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Diffuse Large B-cell Lymphoma
Interventions
OTHER

Patient with histologically confirmed diffuse large B-cell lymphoma with a planned first line treatment by R-CHOP.

"Blood samples will be collected :~* at baseline (before the 1st R-CHOP cycle)~* before the 3d administration of chemotherapy (CT) (i.e. after 2 cycles of CT and same timepoint as interim FDG-PET/CT)~* after the 4th administration of the CT~* at the end of induction (i.e. end of R-CHOP treatment)~* at 24 months after initiation of R-CHOP treatment~* at the time of progression (if progression occurs before 24 months of treatment).~Tumor samples will be collected at baseline (from an archived initial diagnostic tumor specimen) and at the time of progression (if applicable from lymph node biopsy performed as part of a standard of care surgical procedure).~Bone marrow samples will be collected at baseline and at the time of progression (if applicable) only in patients for whom a bone marrow aspiration (BMA) is necessary as part of their standard of care, upon physician's decision."

Trial Locations (1)

31059

Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Institut Claudius Regaud

OTHER